HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Small Business Matters

HBW Insight’s coverage of news and issues impacting small and mid-sized enterprises.

GSCF World Congress: Digital, Data & Innovation In Self-Care

The healthcare industry is sick and in desperate need of disruption, stated Consumer Healthcare Products Association president Scott Melville at the beginning of the final session of the 2022 GSCF World Congress. Thought leaders from Google, past and present, Haleon, IQVIA Consumer Health and Convert Group offered their views on where this disruption might come from. 

Londoners Get J&J Brands 'In Minutes' 24/7 Via Zapp Partnership

Johnson & Johnson's OTC brands including Benadryl, Benylin, Calpol, Imodium, Nicorette and Sudafed, as well as its personal care brands such as Aveeno and Neutrogena, are now available for home delivery 24/7 via the Zapp app to consumers in London, UK.

Futura All Set For US FDA De Novo Application For Eroxon OTC ED Treatment

Futura Medical is preparing to seek approval from the FDA to launch OTC in the US its MED3000 erectile dysfunction treatment, marketed in Europe under the Eroxon brand name. After completing all the necessary studies demonstrating that the gel-based, drug-free product works as a self-care treatment for ED, Futura says it is confident that the soon to be submitted de novo medical device application will be successful and pave the way for a Q1 2023 launch.

CEO Don Frey On Helming Independent Beauty Association In ‘Unprecedented’ Climate

Joining IBA from The Honest Company, where he headed up innovation, Frey aims to promote networking and collaboration within the group’s membership in an environment where in-person events – and travel budgets – still have not returned to pre-pandemic levels. Frey spoke with HBW Insight about his career to date and his goals for IBA in the near and longer terms.

Positive Study Results Put Futura’s OTC Erectile Dysfunction Gel On Track For 2023 US Launch

Positive results from a confirmatory Phase III clinical study puts Futura Medical on track to file a dossier for drug-free erectile dysfunction gel MED3000 with the US Food and Drug Administration by the end of September 2022. This is in line with the company's timeline of approval as an OTC de novo medical device in Q1 2023.

Digital Home-Testing Is The Future, Says Bloom Diagnostics Co-Founder Angelica Kohlmann

With its lateral flow at-home tests for ferritin, thyroid function and ovarian reserves, Swiss medtech firm Bloom Diagnostics thinks it has seen the future of consumer healthcare. HBW Insight speaks to co-founder and board chair Angelica Kohlmann about the firm's Bloom Lab technology and forward-looking plans, including a possible US launch. 

Plantwise Launches Supplement Line Focusing On 'Specialized Retailers'

Plantwise launched its CBD supplements in independent pharmacies in May with consultation consumers might not receive at larger chains.

Hot Flash! Menopause May Not Be Sexy, But Investors Are Warming To Digital Health Solutions

Menopause market is a multi-billion opportunity gaining traction with digital health companies offering solutions to help women manage their symptoms and provide treatment and support. Medtech Insight spoke with three female founders and entrepreneurs, as well as a partner at Lux Capital and clinical lead of ORCHA, about this market. 

Public TV Channel Investment Shows UK CBD Market 'Normalizing'

UK public service TV network Channel 4 says its investment in Cannaray will help bring CBD to the mainstream and shows the country's CBD market is stabilizing.

Arcaea CEO On Biotech’s Promise: Sustainable, Yes, But Ingredient Performance Will Drive Adoption

With biotech, “the entire tree of life starts to become accessible to us ethically and sustainably,” says Arcaea CEO Jasmina Aganovic. Her company, launched in October 2021, is developing custom keratin molecules for skin and hair, as well as new UV filter technology, among other innovations to expand formulators’ toolkits, not just replace problematic ingredients.

'Could Put Us Out Of Business’: US State Bill Pileup Has Small Beauty Set On Federal Preemption

The cosmetics industry has an “optics” problem, and that is creating other issues, namely a growing body of state legislation to address perceived gaps in federal regulatory oversight.

HBW Insight’s Key Takeaways From 2021: #3 Keep Your Eye On AI

The future of digital health will be shaped more than anything else by the rise of artificial intelligence. From body enhancing bio-wearables to camera-based skin diagnostics, the consumer health industry continued to explore the possibilities presented by AI in 2021. However, there are many regulatory and ethical hurdles industry must overcome as we move into 2022 and beyond.